Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Serum CD73 is a prognostic factor in patients with metastatic melanoma and is associated with response to anti-PD-1 therapy
Roberta Turiello, Mariaelena Capone, Diana Giannarelli, et al.
Journal for ImmunoTherapy of Cancer (2020) Vol. 8, Iss. 2, pp. e001689-e001689
Open Access | Times Cited: 49

Showing 1-25 of 49 citing articles:

ATP and cancer immunosurveillance
Oliver Kepp, Lucillia Bezu, Takahiro Yamazaki, et al.
The EMBO Journal (2021) Vol. 40, Iss. 13
Open Access | Times Cited: 160
Glial and myeloid heterogeneity in the brain tumour microenvironment
Brian M. Andersen, Camilo Faust Akl, Michael A. Wheeler, et al.
Nature reviews. Cancer (2021) Vol. 21, Iss. 12, pp. 786-802
Open Access | Times Cited: 144
Cancer immunotherapy: it’s time to better predict patients’ response
Charlotte Pilard, Marie Ancion, Philippe Delvenne, et al.
British Journal of Cancer (2021) Vol. 125, Iss. 7, pp. 927-938
Open Access | Times Cited: 127
Beyond CTLA-4 and PD-1 Inhibition: Novel Immune Checkpoint Molecules for Melanoma Treatment
Dimitrios C. Ziogas, Charalampos Theocharopoulos, Panagiotis-Petros Lialios, et al.
Cancers (2023) Vol. 15, Iss. 10, pp. 2718-2718
Open Access | Times Cited: 46
Immunotherapy in melanoma: Can we predict response to treatment with circulating biomarkers?
Elena Splendiani, Zein Mersini Besharat, Alessia Covre, et al.
Pharmacology & Therapeutics (2024) Vol. 256, pp. 108613-108613
Open Access | Times Cited: 17
Combination therapy for pancreatic cancer: anti-PD-(L)1-based strategy
Lingyue Liu, Xing Huang, Fukang Shi, et al.
Journal of Experimental & Clinical Cancer Research (2022) Vol. 41, Iss. 1
Open Access | Times Cited: 59
Mechanisms of resistance to immune checkpoint inhibitors in melanoma: What we have to overcome?
Dimitrios C. Ziogas, Charalampos Theocharopoulos, Tilemachos Koutouratsas, et al.
Cancer Treatment Reviews (2022) Vol. 113, pp. 102499-102499
Closed Access | Times Cited: 59
Exosomal CD73 from serum of patients with melanoma suppresses lymphocyte functions and is associated with therapy resistance to anti-PD-1 agents
Roberta Turiello, Mariaelena Capone, Elva Morretta, et al.
Journal for ImmunoTherapy of Cancer (2022) Vol. 10, Iss. 3, pp. e004043-e004043
Open Access | Times Cited: 57
CD73 Inhibits cGAS–STING and Cooperates with CD39 to Promote Pancreatic Cancer
Célia Jacoberger-Foissac, Isabelle Cousineau, Yacine Barèche, et al.
Cancer Immunology Research (2022) Vol. 11, Iss. 1, pp. 56-71
Open Access | Times Cited: 42
The Clinical Significance of CD73 in Cancer
Niklas Bach, Riekje Winzer, Eva Tolosa, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 14, pp. 11759-11759
Open Access | Times Cited: 30
Interference of ATP‐Adenosine Axis by Engineered Biohybrid for Amplifying Immunogenic Cell Death‐Mediated Antitumor Immunotherapy
Xin‐Chen Deng, Jun‐Long Liang, Shi‐Man Zhang, et al.
Advanced Materials (2024)
Closed Access | Times Cited: 12
Developing a risk score using liquid biopsy biomarkers for selecting Immunotherapy responders and stratifying disease progression risk in metastatic melanoma patients
Amalia Azzariti, Simona De Summa, Tommaso Maria Marvulli, et al.
Journal of Experimental & Clinical Cancer Research (2025) Vol. 44, Iss. 1
Open Access | Times Cited: 1
Single-cell RNA sequencing reveals distinct cellular factors for response to immunotherapy targeting CD73 and PD-1 in colorectal cancer
Mi‐Ok Kim, Yong Ki Min, Jinho Jang, et al.
Journal for ImmunoTherapy of Cancer (2021) Vol. 9, Iss. 7, pp. e002503-e002503
Open Access | Times Cited: 50
CD39 – A bright target for cancer immunotherapy
Shuwei Guo, Fengfeng Han, Wei Zhu
Biomedicine & Pharmacotherapy (2022) Vol. 151, pp. 113066-113066
Open Access | Times Cited: 35
Inhibitors of the CD73-adenosinergic checkpoint as promising combinatory agents for conventional and advanced cancer immunotherapy
Zoya Kurago, Gang Guo, Huidong Shi, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 19
Deciphering and overcoming Anti-PD-1 resistance in Melanoma: A comprehensive review of Mechanisms, biomarker Developments, and therapeutic strategies
Ruoqi Wang, Yanbin Chen, Yongyi Xie, et al.
International Immunopharmacology (2024) Vol. 132, pp. 111989-111989
Closed Access | Times Cited: 6
Protein kinase inhibitor ceritinib blocks ectonucleotidase CD39 – a promising target for cancer immunotherapy
Laura Schäkel, Salahuddin Mirza, Riekje Winzer, et al.
Journal for ImmunoTherapy of Cancer (2022) Vol. 10, Iss. 8, pp. e004660-e004660
Open Access | Times Cited: 21
Targeting inflamed and non-inflamed melanomas: biological background and clinical challenges
Alice Indini, Daniela Massi, Matteo Pirro, et al.
Seminars in Cancer Biology (2022) Vol. 86, pp. 477-490
Open Access | Times Cited: 20
Emerging Therapeutic Strategies of Different Immunotherapy Approaches Combined with PD-1/PD-L1 Blockade in Cervical Cancer
Yanjun Ge, Yuchen Zhang, Kong‐Nan Zhao, et al.
Drug Design Development and Therapy (2022) Vol. Volume 16, pp. 3055-3070
Open Access | Times Cited: 20
Immunosuppressive capacity of circulating MDSC predicts response to immune checkpoint inhibitors in melanoma patients
Vera Petrova, Christopher Groth, Rebekka Bitsch, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 12
High levels of soluble CD73 unveil resistance to BRAF inhibitors in melanoma cells
Caterina Giraulo, Lavinia Orlando, Elva Morretta, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 177, pp. 117033-117033
Open Access | Times Cited: 4
Soluble immune checkpoint molecules in cancer risk, outcomes prediction, and therapeutic applications
Lin Chen, Yuqing Chao, Wenjing Li, et al.
Biomarker Research (2024) Vol. 12, Iss. 1
Open Access | Times Cited: 4
Small-molecule CD73 inhibitors for the immunotherapy of cancer: a patent and literature review (2017–present)
Alessio Nocentini, Clemente Capasso, Claudiu T. Supuran
Expert Opinion on Therapeutic Patents (2021) Vol. 31, Iss. 10, pp. 867-876
Closed Access | Times Cited: 25
Increased primary breast tumor expression of CD73 is associated with development of bone metastases and is a potential biomarker for adjuvant bisphosphonate use
Nataliia Petruk, Steven L. Wood, Walter M. Gregory, et al.
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access
The inhibitory effect of adenosine on tumor adaptive immunity and intervention strategies
Longsheng Wang, Jie Zhang, Wenxin Zhang, et al.
Acta Pharmaceutica Sinica B (2023) Vol. 14, Iss. 5, pp. 1951-1964
Open Access | Times Cited: 9
Page 1 - Next Page

Scroll to top